Source Paper
Safety and antitumor activity of recombinant soluble Apo2 ligand
Avi Ashkenazi, Roger C. Pai, Sharon Fong, Susan Leung, David A. Lawrence et al.
Journal of Clinical Investigation • 1999
Nonhuman Primate Toxicity Study
Objective: Evaluation of tissue and organ toxicity following repeated intravenous Apo2L (TRAIL) injections in nonhuman primates to assess safety profile for potential cancer therapy
Gather these items before starting the experiment. Check off items as you prepare.
Materials1
Genentech Inc. • Not applicable • Not specified • Not specified
As an Amazon Associate, we earn from qualifying purchases. Product links help support this free resource.
Protocol Steps
Preparation of Apo2L protein
Generate recombinant soluble version of native human Apo2L protein in bacterial expression system
Note: Protein must be potently active for subsequent injections
View evidence from paper
“we generated in bacteria a potently active soluble version of the native human protein”
Repeated intravenous injections in nonhuman primates
Administer repeated intravenous injections of Apo2L to nonhuman primates
Note: Injection schedule and dosage not explicitly detailed in provided text
View evidence from paper
“Repeated intravenous injections of Apo2L in nonhuman primates did not cause detectable toxicity to tissues and organs examined”
Tissue and organ examination
Examine tissues and organs for signs of toxicity following Apo2L treatment
Note: Specific tissues and organs examined not detailed in provided text
View evidence from paper
“Repeated intravenous injections of Apo2L in nonhuman primates did not cause detectable toxicity to tissues and organs examined”